Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin
GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed […]
English
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024
Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting
Isofol Medical AB (publ) publishes interim report, January–March 2024
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration
Isofol presents a clinical development plan for arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy
Isofol invites to investor meeting on March 19
GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an
Isofol Medical AB (publ) publishes year-end report, January – December 2023
GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report
Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19
GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work